Disitamab vedotin

• Target:

  EGFR|||Antibody-Drug Conjugates (ADCs)

• Related Pathways:

  Tyrosine Kinase/Adaptors|||Angiogenesis|||Antibody-drug Conjugate/ADC Related|||JAK/STAT signaling

• Purity:

  0.98

• Bioactivity:

  Disitamab vedotin (RC-48) is a newly developed antibody-active molecule conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), consisting of hertuzumab coupled to monomethyl auristatin E (MMAE) via a cleavable linker. Disitamab vedotin showed anti-tumor and anti-proliferative activities in gastric cancer cells with different HER-2 expression levels and inhibited the expression of HER-2 protein in gastric cancer cells.

• Shipping Conditions:

  Cool pack

• Storage Temperature:

  -20°C

• CAS Number:

  2136633-23-1